TachoSil sealant matrix
- Name:
TachoSil sealant matrix
- Company:
Takeda Products Ireland Ltd
- Active Ingredients:
- Legal Category:
Product subject to restricted prescription (C)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 24/01/20

XPIL
Package leaflet: Information for the user
Package leaflet: Information for the user
1. What TachoSil is and what it is used for
1. What TachoSil is and what it is used for
2. What you need to know before TachoSil is used
2. What you need to know before TachoSil is used
3. How to use TachoSil
3. How to use TachoSil
4. Possible side effects
4. Possible side effects
5. How to store TachoSil
5. How to store TachoSil
6. Contents of the pack and other information
6. Contents of the pack and other information
Click on this link to Download PDF directly
Takeda Products Ireland Ltd

Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 21 May 2020 SPC
Reasons for updating
- Other
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Incorrect document uploaded. Correction made to upload the current SmPC in place of the PIL.
Updated on 24 January 2020 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 24 January 2020 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Section |
Changes |
4.4. Special warnings and precautions for use
|
Deletion / addition of text: Traceability In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
|
4.8 |
Updated to: HPRA Pharmacovigilance Website: www.hpra.ie |
10. date of the revision of the text |
6th December 2019 |
Updated on 22 August 2019 SPC
Reasons for updating
- File format updated to PDF
Legal category: Product subject to restricted prescription (C)
Updated on 8 June 2018 SPC
Reasons for updating
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Minor typographical errors have been corrected and the Date of revision of the text updated to 25th May 2018
Updated on 8 June 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 5 - how to store or dispose
- Change to section 6 - date of revision
Updated on 11 April 2016 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to restricted prescription (C)
Updated on 11 April 2016 SPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Change to section |
Details of change |
4.1 Therapeutic Indications |
Text in blue removed and text in red added:
TachoSil is indicated in adults for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing,
|
4.4 Special warnings and precautions for use |
Text in blue removed and text in red added:
Do not use intravascularly. Life threatening thromboembolic complications may occur if the preparation is applied intravascularly.
Specific data have not been obtained on the use of this product
It is not known whether recent radiation therapy affects the efficacy of Tachosil when used for dura mater sealing.
As with any protein-containing product, allergic type hypersensitivity reactions are possible. Signs of hypersensitivity reactions include hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. If these symptoms occur, the administration has to be discontinued immediately.
|
5.1 Pharmacodynamic properties |
Text in red added:
….. However, the second study investigating tissue sealing in 299 patients (149 TachoSil, 150 standard surgical treatment) with demonstrated intraoperative air leakage showed the superiority of TachoSil compared to standard treatment.
The efficacy of TachoSil was tested in a randomised controlled study in 726 patients (362 treated with TachoSil and 364 controls) undergoing skull base surgery as an adjunct to suture for sealing the dura mater, in which the efficacy outcome was measured post-operatively as verified cerebrospinal fluid (CSF) leaks or pseudomeningocoele, or treatment failure during surgery. In this study, superiority over current practise practice (which included suture, duraplasty and fibrin and polymer sealants or combinations of these) could not be documented. The numbers of subjects experiencing an efficacy outcome event were 25 (6.9%) and 30 (8.2%) for TachoSil and current practice treated patients, respectively, providing an Odds Ratio of 0.82 (95% CI: 0.47, 1.43). However, the 95% confidence intervals for the odds ratio results indicated that TachoSil had similar efficacy to current practice. In this study two application techniques for TachoSil were evaluated: application of TachoSil over the dura and application of TachoSil on both sides of the dura. The results did not support the second method. TachoSil was found to be well tolerated and safe for use as an adjunct to dura mater closure in neurosurgery.
|
6.6 Special precautions for disposal and other handling |
Text in red added:
…
The active side of TachoSil should be applied so that it extends 1‑2 cm beyond the margins of the wound. If more than one matrix is used they should overlap. TachoSil can be cut to the correct size and shaped if too large.
In neurosurgery, TachoSil should be applied on top of the primary dura closure.
Pre-rolled TachoSil can be used for both open surgery and in minimally invasive surgery, and it can pass through a 10 mm or larger port or trocar.
… |
10. Date of revision of the text |
Updated text in red:
30th March 2016 |
Updated on 26 February 2016 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Please note that formatting and typographical corrections have occurred throughout SmPC. Only key additions/deletions to text have been provided below.
Change to section |
Details of change |
||||||||||||||||||||||||||||||
4.4 Special warnings and precautions for use |
Text in red removed:
Do not use intravascularly. Life threatening thromboembolic complications may occur if the preparation is
Text in red added:
As with any protein-containing product, allergic type hypersensitivity reactions are possible. Signs of hypersensitivity reactions include hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. If these symptoms occur, the administration has to be discontinued immediately. |
||||||||||||||||||||||||||||||
4.8 Undesirable effects |
Text in red added/removed:
Immunogenicity: Antibodies against components of fibrin sealant/haemostatic products may occur rarely. However, in a clinical trial with TachoSil in hepatic surgery, in which patients were investigated for the development of antibodies, 26% of the 96 patients tested and treated with TachoSil developed antibodies to equine collagen. The equine collagen antibodies that developed in some patients after TachoSil use were not reactive with human collagen. One patient developed antibodies to human fibrinogen. There were no adverse events attributable to the development of human fibrinogen or equine collagen antibodies. There is very limited clinical data available regarding re-exposure to TachoSil. Two subjects have been re-exposed in a clinical trial and have not reported any immune-mediated adverse events; however, their antibody status to collagen or fibrinogen is unknown.
Thromboembolic complications may occur if the preparation is
Data from the
Tabulated summary of adverse reactions
The following adverse reactions have been reported with TachoSil during post marketing experience. The frequency of all of the events listed below has been categorised as not known (cannot be estimated from the available data).
|
||||||||||||||||||||||||||||||
10. Date of revision of the text |
Updated:
4 February 2016 |
Updated on 23 February 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 23 February 2016 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
- Change to dosage and administration
Updated on 28 January 2016 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
- Change to date of revision
Updated on 28 January 2016 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Change to section |
Details of change |
||||||||||||||||||||
4.4 Special warnings and precautions for use |
Added:
To prevent the development of tissue adhesions at undesired sites, ensure tissue areas outside the desired application area are adequately cleansed before administration of TachoSil (see section 6.6). Events of adhesions to gastrointestinal tissues leading to gastrointestinal obstruction have been reported with use in abdominal surgery carried out in proximity to the bowel.
|
||||||||||||||||||||
4.8 Undesirable effects |
Text in red added:
|
||||||||||||||||||||
6.6 Special precautions for disposal and other handling |
Added text in red:
Pressure is applied with moistened gloves or a moist pad. Due to the strong affinity of collagen to blood, TachoSil may also stick to surgical instruments, gloves or adjacent tissues covered with blood. This can be avoided by cleansing surgical instruments, and gloves and adjacent tissues before application. It is important to note that failure to adequately clean adjacent tissues may cause adhesions (see section 4.4). After pressing TachoSil to the wound, the glove or the pad must be removed carefully. To avoid TachoSil from being pulled loose it may be held in place at one end, e.g. with a pair of forceps.
|
||||||||||||||||||||
10. Date of revision of the text |
Updated:
6 January 2016 |
Updated on 24 August 2015 PIL
Reasons for updating
- Change to marketing authorisation holder
Updated on 23 October 2014 PIL
Reasons for updating
- Change to date of revision
- Introduction of new pack/pack size
- Change to product name
- Addition of information on reporting a side effect.
Updated on 23 October 2014 SPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
CHANGE TO SECTION |
DETAILS OF CHANGE |
1. NAME OF THE MEDICINAL PRODUCT |
Changed:
‘‘TachoSil medicated sponge’’ to ‘’TachoSil sealant matrix’’
|
3. PHARMACEUTICAL FORM |
Changed:
‘‘Medicated sponge’’ to ‘’Sealant matrix’’
‘’TachoSil is an off-white
|
4.2 POSOLOGY AND METHOD OF ADMINISTRATION |
The quantity
Application of TachoSil must be individualised by the treating surgeon. In clinical trials, the individual dosages have typically ranged from 1-3
Method and route of administration For epilesional use
|
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
|
For |
4.8. UNDESIRABLE EFFECTS
|
Added:
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.
|
6.5 NATURE AND CONTENTS OF CONTAINER |
Changed:
Each
Pack sizes: Package with 1 Package with 2 Package with 1 Package with 5
Added: Package with 1 pre-rolled matrix of 4.8 cm x 4.8 cm
|
6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING |
Changed:
After removal of the conventional, flat TachoSil from the sterile package it
Added: After removal of the pre-rolled TachoSil from the sterile package it should be applied immediately through the trocar without pre-moistening. While unrolling the matrix the yellow, active side of the matrix is applied to the bleeding/leaking surface using e.g. a pair of cleansed forceps and held against it with a moist pad under gentle pressure for 3-5 minutes. This procedure enables an easy adhesion of TachoSil to the wound surface.
Changed: This can be avoided by
Changed: The active side of TachoSil
Added: Pre-rolled TachoSil can be used for both open surgery and in minimally invasive surgery, and it can pass through a 10 mm or larger port or trocar.
|
10. DATE OF REVISION OF THE TEXT |
Changed to: 25th September 2014 |
Updated on 27 December 2013 PIL
Reasons for updating
- Change to MA holder contact details
Updated on 8 May 2013 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to restricted prescription (C)
Updated on 8 May 2013 PIL
Reasons for updating
- Change to date of revision
- Change to marketing authorisation holder
Updated on 8 January 2013 SPC
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 5.2 - Pharmacokinetic properties
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
The updated TachoSil SmPC contains additional information in the following section(s):
4.3 Contraindications- Additional contraindication added:
TachoSil must not be applied intravascularly.
5.2 Pharmacokinetic Properties- Rewording and additional information to include:
TachoSil is intended for epilesional use only. Intravascular administration is contraindicated.
As a consequence, intravascular pharmacokinetic studies were not performed in man.
Fibrin Sealants/haemostatics are metabolized in the same way as endogenous fibrin by fibrinolysis and phagocytosis.
In animal studies, TachoSil biodegrades after administration to a wound surface with few remnants left after 13 weeks. Complete degradation of TachoSil was seen in some animals 12 months after its administration to a liver wound, whereas small remnants were still observed in others. The degradation was associated with infiltration of granulocytes and formation of resorptive granulation tissue encapsulating the degraded remnants of TachoSil. No evidence of local intolerability has been observed in animal studies.
From the experience in humans there have been isolated cases where remnants were observed as coincidental findings with no signs of functional impairment
Updated on 8 January 2013 PIL
Reasons for updating
- Change to improve clarity and readability
Updated on 14 October 2011 PIL
Reasons for updating
- Improved electronic presentation
Updated on 29 July 2010 PIL
Reasons for updating
- Change to MA holder contact details
Updated on 23 July 2010 SPC
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Section 6.5
Each sponge is packed in a polystyrene blister sealed with a peel lacquer laminate paper. The blister is packed in an aluminium-bonded foil sachet with a desiccant bag included and packed in a folding carton.
Section 6.5
Each sponge is packed in a PET-GAG blister sealed with a coated PE foil. The blister is packed in an aluminium-bonded foil sachet with a desiccant bag included and packed in a folding carton.
Updated on 26 May 2009 SPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Updated on 21 January 2008 PIL
Reasons for updating
- Change to MA holder contact details
- Change to date of revision
Updated on 13 December 2006 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category: Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
- Section 2: 'a full list of' added in last sentence to read 'For a full list of excipients, see section 6.1'
- Section 4.4: heading amended in line with updated EMEA guidance (on original document)
- Section 5.1: ATC code updated to B02BC30
- Section 6.6: heading amended in line with updated EMEA guidance (on original document)
- Section 10: Date of revision, 08 November 2006
Updated on 23 June 2006 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 21 June 2006 SPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to restricted prescription (C)